Cell Reconstitution Media (Michael A. Matthay)

Cell Reconstitution Media is a specific formulation used as the placebo control in the Phase 2b STAT clinical trial (NCT03818854) for the treatment of acute respiratory distress syndrome (ARDS). Developed under the leadership of Michael A. Matthay at the University of California, San Francisco, this media consists of a 1:1 mixture of 5% human serum albumin and 10% Dextran 40. In the trial, it served as the vehicle for the investigational allogeneic bone marrow-derived human mesenchymal stromal cells (hMSCs) and as the standalone control arm. The trial primarily focused on patients with COVID-19-related ARDS but found no significant clinical benefit from the MSC treatment compared to this placebo media.

Other names

5% human serum albumin + 10% Dextran 40reconstitution media